Home>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>E3 Ligase Ligand-Linker Conjugates 21

E3 Ligase Ligand-Linker Conjugates 21 (Synonyms: Cereblon Ligand-Linker Conjugates 3 ; E3 Ligase Ligand-Linker Conjugates 14)

Catalog No.GC33103

E3 Ligase Ligand-Linker Conjugates 21 (Cereblon Ligand-Linker Conjugates 3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

Products are for research use only. Not for human use. We do not sell to patients.

E3 Ligase Ligand-Linker Conjugates 21 Chemical Structure

Cas No.: 1957236-20-2

Size Price Stock Qty
5mg
$45.00
In stock
10mg
$63.00
In stock
25mg
$90.00
In stock
50mg
$162.00
In stock
100mg
$252.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

E3 Ligase Ligand-Linker Conjugates 21 is a synthesized compound that incorporates an E3 ligase ligand and a linker used in PROTAC technology.

E3 Ligase Ligand-Linker Conjugates 21 is composed of Degron (E3 ubiquitin ligase) and a linker, and they are used in PROTAC technology. E3 Ligase Ligand-Linker Conjugates 21 binds to the targeting ligand to induce the target protein (including BRD4, BRD2, and BRD3) degradation[1].

[1]. Methods to induce targeted protein degradation through bifunctional molecules. WO 2017007612 A1

Reviews

Review for E3 Ligase Ligand-Linker Conjugates 21

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for E3 Ligase Ligand-Linker Conjugates 21

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.